Multi-organ toxicity profiles for 99 antibody-drug conjugates

Scope: only ADCs with assessed ocular-adverse-event (OAE) data are included (a reported ocular rate, or documented as ocular-clear).

Adverse-event rates across eight organ systems with an ocular focus, payload and linker chemistry, and eye-tissue target-expression rates. Click a column to rank all 99 ADCs on that organ; click a row for the full profile.

Aggregate viewsPayloads & linkers Molecular targets

agents →

All 99 agents have assessed ocular data - 74 reported an ocular event, 25 were assessed and clear (a true 0%, not missing data).

low

severe

99 ADCs · sorted by ocular ↓

	ADC	Target	Payload class	Ocular ↓	Hepatic	Neutrop.	Thrombo.	Anemia	GI	ILD	Neuro.
1	A166	ERBB2	Auristatin	100	18.5	10.8	4.6	23.5	10.8	3.1	53.1
2	DP-303c	ERBB2	Auristatin	94.7	31.9	14.9		26.6		4.3	46.8
3	Depatuxizumab mafodotin	EGFR	Auristatin	94	40.5	7.1	61	29.8	14.3
4	Belantamab mafodotin	TNFRSF17	Auristatin	92	88	52	100	51	32	26
5	AGS-16C3F	ENPP3	Auristatin	85	7.6		35.3	29.4	55.9		8
6	Denintuzumab mafodotin (NHL)	CD19	Auristatin	84					29
7	Trastuzumab duocarmazine	ERBB2	DNA alkylator	78.1	5.5	15.8	5.5	10.3	18.5	7.6
8	IMGC-936	ADAM9	Maytansinoid	77.8	7.7	0	10	38.5	23.1	15.4	0
9	CRB-701 (SYS6002)	NECTIN4	Auristatin	66	27		18.9	21	18.9		8.4
10	ZV0203	ERBB2	Auristatin	60	40	26.7		26.7		0
11	Mirvetuximab soravtansine	FOLR1	Maytansinoid	59	57	22	17	18	29	10	36
12	Vorsetuzumab mafodotin	CD70	Auristatin	57			26		30
13	JBH-492	CCR7	Maytansinoid	56.3	50	4	8		43	4
14	Denintuzumab mafodotin (ALL)	CD19	Auristatin	56			18	34	52
15	FS-1502	ERBB2	Auristatin	55.3	66.7		34	26.7	33.3	3.3
16	Tisotumab vedotin	F3	Auristatin	55	34	16		41	33	2	38
17	MEDI2228	TNFRSF17	PBD dimer	53.7	24.4		31.7
18	Cantuzumab ravtansine	MUC1	Maytansinoid	50
19	Praluzatamab ravtansine	ALCAM	Maytansinoid	49	22.2	2	4	9.1	46.5		16.2
20	Iladatuzumab vedotin	CD79B	Auristatin	47	8	27			20	5	20
21	MYTX-011	MET	Auristatin	47	33	0	0	5	36		36
22	ARX788	ERBB2	Auristatin	46.4	70.9	23.3	36.7	25	20	34.8
23	ARX-305	CD70	Auristatin	46.3	58.5		29.3	43.9
24	Zanidatamab zovodotin (ZW49)	ERBB2	Auristatin	45					29	0
25	XB-002 (Samatatug zovodotin)	F3	Auristatin	42
26	Upifitamab rilsodotin	SLC34A2	Auristatin	41	69		49.6	39.2	51.9	9.6
27	Aprutumab ixadotin	FGFR2	Auristatin	40	60		50	30	25
28	Enfortumab vedotin	NECTIN4	Auristatin	40	75	27		28	35	3	53
29	PF-06263507	TPBG	Auristatin	38.5	11.5		23.1	7.7	23.1		7.7
30	Datopotamab deruxtecan	TACSTD2	Topoisomerase I inhibitor	38	24	30		35	56	2.4
31	Tusamitamab ravtansine	CEACAM5	Maytansinoid	38		1.1	1.1	3.3	22.8		13
32	Anetumab ravtansine	MSLN	Maytansinoid	37	29		21	16	58		37
33	SAR-566658	MUC1 (CA6 epitope carried on MUC1)	Maytansinoid	36
34	AGS-16M8F	ENPP3	Auristatin	31			30.8		30.8
35	TRPH-222	CD22	Maytansinoid	31							9.1
36	AMG-224	TNFRSF17	Maytansinoid	30	45.5	27.3	72.7	27.3	36.4		9.1
37	Sirtratumab vedotin	SLITRK6	Auristatin	29					37.6		19.4
38	MRG-004A	F3	Auristatin	27				17
39	Coltuximab ravtansine	CD19	Maytansinoid	25	79	84	57	87	23		8
40	Telisotuzumab vedotin	MET	Auristatin	25	41	10	14	35	15	10	51
41	Samrotamab vedotin (ABBV-085)	LRRC15	Auristatin	24.4					19		31
42	SYSA-1801	CLDN18	Auristatin	21.2
43	Lifastuzumab vedotin	SLC34A2	Auristatin	20	22	73	61	32	49	34	61
44	Vobramitamab duocarmazine	CD276	Duocarmycin	19.8	5.8	25.6	14	26.7	30.2	2.3	4.7
45	LY3076226 (IMC-D11)	FGFR3	Maytansinoid	12	28	0	20	12	44	0	16
46	Trastuzumab deruxtecan	ERBB2	Topoisomerase I inhibitor	11	67	70	52	64	76	11	13
47	AB-160	VEGFA	Taxane	10	30	90	30	100	100	10	90
48	BMS-986148	MSLN	Tubulysin	10	49				32
49	DLYE5953A (RG-7841)	LY6E	Auristatin	10	16	13		12	38		35
50	JK-06	TPBG	Auristatin	10					10
51	PF-06804103	ERBB2	Auristatin	9.5	17.9	5.3	2.1	25.3	30.5	1.1	32.6
52	Pinatuzumab vedotin	CD22	Auristatin	9.5							59
53	Farletuzumab ecteribulin	FOLR1	Microtubule (other)	9	20.8	45		27	33.3	23	6.7
54	Moxetumomab pasudotox	CD22	Other	9	65	41	21	43	35
55	AVID-100	EGFR	Maytansinoid	8	20		24	4	32
56	PF-06647263	EFNA4	Calicheamicin	8	12	4	28	16	60		8
57	Serclutamab talirine (ABBV-321, EGFR, PBD/SGD-1882)	EGFR	PBD dimer	7	21		18	5	18	2
58	PF-06664178	TACSTD2	Auristatin	6.5
59	Indatuximab ravtansine	SDC1	Maytansinoid	6.3
60	BRY-812	SLC39A6	Auristatin	5.9
61	MEN-1309 (OBT076)	LY75	Maytansinoid	5.9		41		41
62	Brentuximab vedotin	TNFRSF8	Auristatin	5	31	54	28	33	42	25	52
63	Disitamab vedotin	ERBB2	Auristatin	5	42.1	42.1	24.3	21.5	29		68.2
64	PF-06650808	NOTCH3	Auristatin	5	12.5	15	2.5	20	40		10
65	Sacituzumab govitecan	TACSTD2	Topoisomerase I inhibitor	5	27	78	23	94	59	24	18
66	Trastuzumab emtansine	ERBB2	Maytansinoid	5	98	39	83	60	40	1.2	21
67	Lorvotuzumab mertansine	NCAM1	Maytansinoid	4.7	16.5				30.9		17.5
68	Trastuzumab rezetecan	ERBB2	Topoisomerase I inhibitor	3.3	42.9	79.4	42.9	76.2	79.4	11.6
69	SC-002 (rovalpituzumab, DLL3, PBD/SG3199)	DLL3	PBD dimer	2.9
70	Patritumab deruxtecan	ERBB3	Topoisomerase I inhibitor	2.7	16.9	37.3	43.6	32.9	65.3	5.3
71	Sacituzumab tirumotecan	TACSTD2	Topoisomerase I inhibitor	2.3	25	74	41	80	44	3	0
72	Polatuzumab vedotin	CD79B	Auristatin	1.2	26	60	32	68	42	1.7	53
73	Camidanlumab tesirine	IL2RA	PBD dimer	0.9	31.6	16.2	20.5	24.8	27.4	3.4	6.8
74	Rovalpituzumab tesirine	DLL3	PBD dimer	0.54	13	9	22	11	24	1.9
75	ATG-022	CLDN18	Auristatin	0	10.8			37.8	37.8
76	BAT-8006	FOLR1	Topoisomerase I inhibitor	0					37	0
77	BAT-8008	TACSTD2	Topoisomerase I inhibitor	0		53.2	34.2	79.1	57.6
78	BYON-3521	MET	Duocarmycin	0					29	3.2
79	Cetuximab saratolacan	EGFR	Photosensitizer	0				16.7	23.3
80	DMOT4039A	MSLN	Auristatin	0		12		17	37		19
81	EBC-129	CEACAM5; CEACAM6	Auristatin	0	17	31	22	17	39		6
82	Farletuzumab (naked Ab)	FOLR1	N/A (naked antibody)	0	25	51	33.3	42.4	16		19.6
83	FOR-46	CD46	Auristatin	0	21	70		30	39		45
84	Gemtuzumab ozogamicin	CD33	Calicheamicin	0	51				21
85	Glembatumumab vedotin	GPNMB	Auristatin	0	11.7	39.4		16.9	44.1		36.2
86	HDP-101	TNFRSF17	Amatoxin	0		22	56	33
87	Indusatumab vedotin	GUCY2C	Auristatin	0	28.6	25	17.9	39.3	52.6	0	10.5
88	Inotuzumab ozogamicin	CD22	Calicheamicin	0	71	94	98	94	31
89	Loncastuximab tesirine	CD19	PBD dimer	0	57	52	58	51	23
90	M-9140	CEACAM5	Topoisomerase I inhibitor	0	12.5	42.5	35	57.5	12.5
91	OBI-999	-	Auristatin	0				33.3			0
92	Rinatabart sesutecan	FOLR1	Topoisomerase I inhibitor	0					70	0	0
93	SC-011 / ABBV-011 (SC17, SEZ6, calicheamicin)	SEZ6	Calicheamicin	0	35		40	15	45
94	STRO-001	CD74	Maytansinoid	0							0
95	TORL-1-23	CLDN6	Auristatin	0	11.9	31		25	29	0	25
96	Vadastuximab talirine	CD33	PBD dimer	0	5	18	44	38	34
97	XMT-1660 (Emiltatug ledadotin)	VTCN1	Auristatin	0	38	0	0		29	0	0
98	XNW-27011	CLDN18	Topoisomerase I inhibitor	0				67.9	59.5	0	0
99	Zilovertamab vedotin	ROR1	Auristatin	0	23	31.4		13	27.5		48

Cells are any-grade (or grade-3+) adverse-event rates, %. = assessed & clear (true 0%); hatched = not assessed.